Advances in the pharmacological treatment of hepatic alveolar echinococcosis: From laboratory to clinic.

Abstract

Hepatic alveolar echinococcosis (HAE) is a zoonotic parasitic disease caused by the larvae of Echinococcus multilocularis. Because of its characteristics of diffuse infiltration and growth similar to tumors, the disability rate and mortality rate are high among patients. Although surgery (including hepatectomy, liver transplantation, and autologous liver transplantation) is the first choice for the treatment of hepatic alveolar echinococcosis in clinic, drug treatment still plays an important and irreplaceable role in patients with end-stage echinococcosis, including patients with multiple organ metastasis, patients with inferior vena cava invasion, or patients with surgical contraindications, etc. However, Albendazole is the only recommended clinical drug which could exhibit a parasitostatic rather than a parasitocidal effect. Novel drugs are needed but few investment was made in the field because the rarity of the cases. Drug repurposing might be a solution. In this review, FDA-approved drugs that have a potential curative effect on hepatic alveolar echinococcosis in animal models are summarized. Further, nano drug delivery systems boosting the therapeutic effect on hepatic alveolar echinococcosis are also reviewed. Taken together, these might contribute to the development of novel strategy for advanced hepatic alveolar echinococcosis.

• Authors: Xiaolei Xu, Xinye Qian, Cancan Gao, Yuan Pang, Hu Zhou, Lizhen Zhu, Zhan Wang, Mingquan Pang, Defang Wu, Wenhao Yu, Fanyu Kong, Dalin Shi, Yuting Guo, Xiaoxia Su, Wang Hu, Jun Yan, Xiaobin Feng, Haining Fan
• Journal: Frontiers in microbiology (Front Microbiol) Vol. 13 Pg. 953846 ( 2022) ISSN: 1664-302X [Print] Switzerland
• PMID: 36003932 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022 Xu, Qian, Gao, Pang, Zhou, Zhu, Wang, Pang, Wu, Yu, Kong, Shi, Guo, Su, Hu, Yan, Feng and Fan.